preloader

2194(E)

(Published in Part II, Section 3, Sub Section (ii) of the 
Gazette of India Extraordinary)

Government of India
Ministry of Chemicals and Fertilizers
Department of Pharmaceuticals
(National Pharmaceuticals Pricing Authority)

                                                                New Delhi, the 23rd June, 2016

ORDER

S.O.2194(E)  – In exercise of the powers conferred by paragraphs 5, 11 and 15 of the Drugs (Prices Control) Order, 2013, read with S.O. 1394(E) dated the 30th May, 2013 and S.O. 701(E) dated 10th March, 2016 issued by the Government of India in the Ministry of Chemicals and Fertilizers, the National Pharmaceutical Pricing Authority (hereinafter referred as NPPA) hereby fixes the price as specified in column (6) of the table herein below as the retail price, exclusive of local taxes, if any in relation to the formulation specified in the corresponding entry in column (2) of the said Table with the strength, unit and name of manufacturer & marketing company respectively, as specified in the corresponding entries in columns (3), (4) and (5) thereof;

Table

Sl. No. Name of the Scheduled Formulation / Brand Name Strength Unit Manufacturer & Marketing Company respectively Retail Price (Rs.)
(1) (2) (3) (4) (5) (6)
1 Diclofenac Sodium Injection
(Volitra AQ)
Each ml contains:
Diclofenac sodium-75mg
1 ml M/s Akums Drugs & Pharmaceuticls Ltd. &
M/s Sun Pharmaceutical Industries Ltd.
14.30
2 Metformin HCl +
Gliclazide Tablet
(Glychek M OD 60)
Each uncoated bilayered
sustained release tablet contains:
Metformin HCl-500mg
(In extended release form)
Gliclazide-60mg
(In modified release form)
1 Tablet M/s Swiss Garnier Genexiaa Sciences &
M/s Indoco Remedies Pvt. Ltd.
7.98
3 Albendazole+
Ivermectin Tablet
(Zenebend Plus)
Each uncoated tablet contains:
Albendazole-400mg
Ivermectin-6mg
1 Tablet M/s Samson Lab. Pvt. Ltd. &
M/s Galpha Lab. Ltd.
15.20
4 Moxifloxacin HCl +
Cefixime Tablet
(Zifi-Max)
Each film coated sustained
release tablet contains:
Moxifloxacin HCl eq. to
Moxifloxacin-400mg
Cefixime (as trihydrate) eq. to
anhydrous cefixime-400mg
1 Tablet M/s Malik Lifescience Pvt. Ltd. &
M/s FDC Ltd.
34.46
5 Dicyclomine HCl Tablet Each uncoated tablet contains:
Dicyclomine HCl-20mg
1 Tablet M/s Meridian Enterprises Pvt. Ltd. 0.85
6 Rabeprazole Sodium+
Domperidone Capsule
Each hard gelatin capsule contains:
Rabeprazole sodium-40mg
(as reddish brown coloured enteric coated pellets)
Domperidone-30mg
(as orange coloured sustained release pellets)
1 Capsule M/s Windlas Biotech Ltd. &
M/s Intas Pharmaceuticals Ltd.
7.19
7 Metformin HCl+
Gliclazide Tablet
(Glychek M OD 30)
Each uncoated bilayered sustained
release tablet contains:
Metformin HCl-500mg
(In extended release form)
Gliclazide-30mg
(In modified release form)
1 Tablet M/s Swiss Garnier Genexiaa Sciences &
M/s Indoco Remedies Pvt. Ltd.
4.96
8 Clindamycin Phosphate +
Hydrous Benzoyl Peroxide Gel
Each gm contains:
Clindamycin Phosphate eq. to
Clindamycin-1% w/v
Hydrous Benzoyl Peroxide eq. to
anhydrous benzoyl Peroxide-2.5% w/w
1 Gram M/s Cadila Pharmaceuticals Ltd. 13.31
9 Telmisartan+
Indapamide Tablet
(Telma D)
Each uncoated bilayered tablets contains:
Telmisartan-40mg
Indapamide-1.5mg
(as sustained release form)
1 Tablet M/s Windlas Biotech Ltd.&
M/s Glenmark Pharmaceuticals Ltd.
8.84
10 Tramadol HCl +
Diclofenac Sodium Tablet
(Dolinsta)
Each film coated bilayered tablet contains:
Tramadol HCl-50mg
Diclofenac Sodium-75mg
(as sustained release form)
1 Tablet M/s Sunglow Pharmaceuticals (P) Ltd. &
M/s Indoco Remedies Pvt. Ltd.
10.08
11 Paracetamol Injection
(Paralup IV)
Each 100ml contains:
Paracetamol-1gm
1 injection (100ml) M/s Eurolife Healthcare Pvt. Ltd. &
M/s Lupin Ltd.
206.00
12 Telmisartan+
Nebivolol HCl Tablet
(Telma NB)
Each uncoated bilayered
tablets contains:
Telmisartan-40mg
Nebivolol HCl eq. to Nebivolol-5mg
1 Tablet M/s Windlas Biotech Ltd.&
M/s Glenmark Pharmaceuticals Ltd.
11.04

 

NOTE :

  1. The manufacturers of above mentioned formulations i.e. “new drug” under paragraph 2(u) of the DPCO, 2013 shall fix the retail price as specified in column (6) of the table hereinabove.
  2. The manufacturers may add local taxes only if they have paid actually or it is payable to the Government on the retail price mentioned in column (6) of the above said table.
  3. The retail price for a pack of the aforesaid formulation shall be arrived at by the concerned manufacturers in accordance with the retail price specified in column (6) of the above table as per provisions contained in paragraph 11 of the DPCO, 2013. The manufacturers shall issue a price list in Form-V from date of Notification as per paragraph 24 of the DPCO, 2013.
  4. The above mentioned retail price is applicable only to the individual manufacturers/marketeers as mentioned above i.e. who have applied for the same by submitting Form-I for price fixation / revision as stipulated under DPCO, 2013 and subject to fulfillment of all the applicable statutory requirements as laid down by the Govt. under relevant statutes/ rules, including manufacturing license permission from the Competent Authority i.e. the Central/State Licensing Authority, as may be applicable, by the concerned manufacturers/marketing companies.
  5. The concerned manufacturers of above said formulations shall furnish quarterly return to the NPPA, in respect of production / import and sale of product in Form-III of Schedule-II of the DPCO, 2013. Manufacturers, in case intending to discontinue above said formulations, shall furnish information to the NPPA, in respect of discontinuation of the production and / or import of above said formulation in Form-IV of Schedule-II of the DPCO, 2013 at least six months prior to the intended date of discontinuation.
  6. In case the retail price of any of the aforesaid formulations is not complied with, as per instant price notification and notes specified hereinabove, then the concerned manufacturer/marketing company shall be liable to deposit the overcharged amount along with the interest thereon under the provisions of the DPCO, 2013 read with the Essential Commodities Act, 1955.
  7. Consequent to the issue of retail price of the aforesaid formulations as specified in column (2) of the above mentioned table in this notification, the price order(s) if any, issued for concerned manufacturer / marketeer prior to the above said date of notification, stand(s) superseded.

PN/165/33/2016/F

F.No. 8(33)/2016/D.P./NPPA-Div.II

(BALJIT SINGH)
Assistant Director
National Pharmaceutical Pricing Authority

Last Page Updated: 09-01-2019